Scientific Industries, Inc.

What they do

The Company operates in two segments: Benchtop Laboratory Equipment (Torbal and VIVID brands of balances, scales, force gauges, pill counters, and moisture analyzers) and Bioprocessing Systems (via SBHI, SBI, and aquila biolabs GmbH, offering products like the Cell Growth Quantifier, Liquid Injection System, and DOTS-branded sensors). Products serve universities, pharmaceutical companies, pharmacies, and laboratories. The Genie product line was sold on August 7, 2025.

Revenue drivers

• Benchtop Laboratory Equipment (Torbal/VIVID) — Sales of balances, scales, force gauges, pill counters, and moisture analyzers; revenue increased approximately $645,100 in FY2025, primarily from Torbal division products.
• Bioprocessing Systems — Sales of bioprocessing products including CGQ, LIS, and DOTS MPS sensors; sales decreased in FY2025 but increased $227,700 in Q1 2026.

Recent performance

For FY2025, net revenues were $5.05 million, up 5.4% from $4.80 million in 2024, with a gross margin of 25.8% (impacted by inventory write-offs; 42.6% without them). The Company reported a loss from continuing operations of $1.78 million in 2025, improved from an $8.02 million loss in 2024, helped by a $5.26 million gain on the Genie sale. In Q1 2026, revenue was $1.23 million, up 30.2% year-over-year, with a gross margin of 38.3% and a pre-tax loss of $1.59 million.

Strategy

Management is prioritizing the Bioprocessing Systems segment, investing in new product development (e.g., DOTS MPS) while also supporting the VIVID line. Cost-cutting initiatives have reduced G&A, selling, and R&D expenses, particularly in bioprocessing. The Company is using proceeds from the Genie sale to fund operations and has generated interest income from investment securities.

Risks

• Limited financial resources — The Company has cash of $616,500 as of June 30, 2026, and expects to need additional funding to continue bioprocessing development and commercialization.
• Dependence on new product success — Future revenue growth depends on market acceptance of new bioprocessing products like DOTS MPS, which have not yet generated significant sales.
• Potential inability to raise capital — No committed external funding sources; if additional financing is not available, the Company may have to delay or reduce product development programs.
• Inventory write-off risk — The Bioprocessing segment recorded inventory write-offs of slow-moving items in FY2025, which could recur if demand does not materialize.

Outlook

Management expects to continue investing in bioprocessing product development and commercialization, with a focus on generating meaningful revenues. The Company will continue cost-saving initiatives and may need to raise additional capital. No specific revenue or profitability guidance was provided.